首页> 外文期刊>Clinical practice and epidemiology in mental health >The impact of prescribed psychotropics on youth
【24h】

The impact of prescribed psychotropics on youth

机译:处方精神药物对青少年的影响

获取原文
           

摘要

Many psychotropics prescribed to children are unlicensed or off-label. This article uses the two most prescribed psychotropics (MPH and SSRIs) to illustrate various concerns about their impact on youth. Many mental illnesses begin in childhood or early adulthood, warranting a treatment of some kind. However, commentators have argued that prescribing is influenced by five myths: (1) children are little adults; (2) children have no reason to develop depression or anxiety; (3) psychiatric disorders are the same across adults and children; (3) children can be prescribed lower doses of the same drug; (5) drugs are preferable to alternative treatments and are more successful. Several lines of evidence suggest that these are incorrect assumptions. We update readers with recent research in relation to these myths, concluding that researchers should clarify child/adult differences for psychotropics, attend to the growth of "cosmetic" use of psychotropics in children and adolescents, and address concerns about the diagnostic validity of mental illness in the current DSM classification system.
机译:开给儿童的许多精神药物是未经许可的或没有标签的。本文使用两种处方药最多的精神药物(MPH和SSRI)来说明有关其对青少年影响的各种担忧。许多精神疾病始于儿童期或成年初期,因此需要进行某种治疗。但是,评论员认为开处方受五个神话的影响:(1)儿童是成年人。 (2)儿童没有理由发展为抑郁或焦虑症; (3)成年人和儿童的精神疾病相同; (3)可以给儿童开更低剂量的相同药物; (5)药物比替代治疗更可取,并且更成功。有几条证据表明这是错误的假设。我们为读者提供有关这些神话的最新研究成果,并得出结论,研究人员应阐明儿童/成人在精神药物方面的差异,关注儿童和青少年对精神药物的“美容”使用,并解决对精神疾病诊断有效性的关注在当前的DSM分类系统中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号